Medical Health & Life Science Research News

Report explores the PARP inhibitor industry analysis and forecasts to 2020

Medical Market Research

The report analyses the global Lynparza market in detail along with the regional analysis as it is the only commercialized product in the market. The clinical trials of Niraparib, Rucaparib, Talazoparib and Veliparib are also summarized along with the anticipated market commencement for each of the products.

- Advertising -

This report “Global PARP Inhibitor Market” provides an in-depth analysis of the global PARP inhibitor market with detailed analysis of market size on the basis of value along with the comprehensive examination of each of the segments of the market, namely, Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib.

Complete report available at

Company Coverage of PARP Inhibitor Market: AstraZeneca PLC, AbbVie Inc., Clovis Oncology, Inc., Medivation, Inc., Tesaro, Inc. 

- Advertising -

The report provides detailed market potential of PARP inhibitor in Ovarian cancer, Breast cancer, Prostate cancer and Pancreatic cancer. This section provides the detailed analysis of the clinical trials of various PARP inhibitors for the concerned cancer treatment.

The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall global PARP inhibitor market has also been forecasted for the period 2016-2020, taking into consideration the research & development, the growth drivers and the current and future trends.

The competition in the global PARP inhibitor market is stiff and dominated by the big players like AstraZeneca. Further, key players in the market, AbbVie, Clovis Oncology, Medivation and Tesaro are also profiled with their financial information and respective business strategies.

Access a copy of this research report at

The global PARP inhibitor market has flourished since 2015 as in late 2014, the first PARP inhibitor product was launched and projections are made that the market would rise in the next five years i.e. 2016-2020 tremendously. The market is spread across the globe with the United States and Europe dominating the market.

The PARP inhibitor market can be segmented on the basis of the products into Lynparza, Niraparib, Rucaparib, Talazoparib and Veliparib. Currently, Lynparza is the only commercialized product in the market while other four products are in the development/trial stage.

The market for Veliparib is expected to flourish since 2017 while the markets for Niraparib, Rucaparib and Talazoparib is expected to commence from 2018.

The major growth drivers for the global PARP inhibitor industry are: rise in cancer incidences and PARP inhibitors in clinical routine. Despite the market is governed by growth drivers, there are certain challenges faced by the market such as: side-effects of PARP inhibitors and resistance to PARP inhibition.

Some of the recent and major trends in the market include, various PARP inhibitors in the pipeline, inhibiting enzyme versus PARP trapping, the combination of PARP inhibitor & c-MET and pill burden likely to decline in the near future.

Few Points from List of Tables:

Table 1: DDR Drug Portfolio

Table 2: PARP Inhibitors in Development

Table 3: Ongoing Phase III and Phase II Lynparza Trials

Table 4: Ongoing Niraparib Trials

Table 5: Ongoing Phase III and Phase II Rucaparib Trials

Table 6: Ongoing Talazoparib Trials

Table 7: Ongoing Phase III and Phase II Veliparib Trials

Table 8: Global PARP Inhibitor Market Potential

Table 9: Phase III Ovarian Cancer Trials

Table 10: Phase III Breast Cancer Trials

Table 11: Prostate Cancer Trials

Table 12: Pancreatic Cancer Trials

Table 13: Enzyme Inhibition and PARP Trapping Capabilities of Each PARP

Table 14: Global PARP Inhibitor Major Companies Ongoing Phase III Trial

Table 15: AstraZeneca Major Products

News From

MarketReportsOnline - Industry Research Analysis StoreMarketReportsOnline
Category: Market Research Publishers and RetailersCompany about: MarketReportsOnline comprises of an online library of 2,50,000 reports and in-depth market research studies of over 5000+ micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports.